Search
Showing results for "Childhood interstitial lung disease "
The molecular studies of Professor Wayne Thomas, particularly on house dust mites, have provided new understandings of allergy and new diagnostics.
Six researchers from The Kids Research Institute Australia have been awarded $8.9 million in prestigious Investigator Grants from the National Health and Medical Research Council.
The role of honey for the treatment of skin infections and wound healing has primarily come from personal stories of its effectiveness however these personalised studies have not been researched in the Kimberley region.
In this article, we examine the utility of a transdiagnostic, dimensional approach to very early identification and intervention for infants at risk of neurodevelopmental disorders
This blog aims to explore what emotions are, why they are important, and how we can support children to develop their ability to understand and express their own emotions in a healthy way.
Embrace has appointed Professor of Clinical Psychology Jeneva Ohan as its new Co-Director alongside Professor Helen Milroy AM.
Nick Raelene Terrance Gottardo Endersby Johns MBChB FRACP PhD BSc (Hons) PhD Head of Paediatric and Adolescent Oncology and Haematology, Perth
ORIGINS is Australia's largest longitudinal cohort study of its kind. Following 10,000 WA children from their time in the womb into early childhood, ORIGINS researchers are working to better understand when and why non-communicable diseases develop, and provide solutions for early intervention to ensure every child and family flourishes throughout their lifetime.
Antimicrobial resistance (AMR) is a global healthcare emergency, directly causing 1.3 million deaths per year and predicted to increase dramatically over the coming decades. Understanding the molecular mechanisms underpinning antibiotic resistance is central to approaches for AMR surveillance and diagnosis in a clinical laboratory.
The antirelapse efficacy of primaquine is related to the total dose administered, whereas the risks of haemolysis and gastrointestinal intolerance are associated with the daily dose administered. National Malaria Control Programmes require local information on efficacy, tolerability and safety to optimize antimalarial treatment policies for Plasmodium vivax malaria control and elimination efforts.